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Traditionally it has taken years or decades for new public health interventions
targeting diseases found in developing countries to be accessible to those most in
need. One reason for the delay has been insufficient anticipation of the eventual
processes and evidence required for decision making by countries. This paper
describes research into the anticipated processes and data needed to inform
decision making on malaria vaccines, the most advanced of which is still in
phase 3 trials. From 2006 to 2008, a series of country consultations in Africa led
to the development of a guide to assist countries in preparing their malaria
vaccine decision-making frameworks. The guide builds upon the World Health
Organization’s Vaccine Introduction Guidelines. It identifies the processes and
data for decisions, when they would be needed relative to the development
timelines of the intervention, and where they will come from. Policy develop-
ment will be supported by data (e.g. malaria disease burden; roles of other
malaria interventions; malaria vaccine impact; economic and financial issues;
malaria vaccine efficacy, quality and safety) as will implementation decisions
(e.g. programmatic issues and socio-cultural environment). This generic guide
can now be applied to any future malaria vaccine. The paper discusses the
opportunities and challenges to early planning for country decision-making—
from the potential for timely, evidence-informed decisions to the risks of
over-promising around an intervention still under development. Careful and
well-structured planning by countries is an important way to ensure that new
interventions do not remain unused for years or decades after they become
available.
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KEY MESSAGES
 Insufficient planning for decision-making processes—and a lack of early gathering of data to inform those processes—is a
key reason for often long delays between development and availability of new interventions in low- and middle-income
countries.
 The PATH Malaria Vaccine Initiative (MVI) and the World Health Organization (WHO) worked with countries years
before projected availability of any malaria vaccine to anticipate the country processes and data needed for eventual
decisions on use.
 Planning should be cautiously paced to not get ahead of, or over-promise, relative to evidence from the intervention’s
development progress.
Introduction
An increasing amount of money, US$3.2 billion dollars in 2009
alone, is being spent on research and development for new
products intended to address diseases prevalent in the develop-
ing world (Policy Cures 2010). Assuming that even a fraction of
these funds realizes the goal of creating new health interven-
tions, low- and middle-income countries (LMICs) will face a
growing number of decisions on which new interventions to
use in the coming decade.
This paper focuses on national decisions to adopt, or not, a
new intervention, once it becomes available (i.e. approved by
the appropriate regulatory authorities and produced in suffi-
cient quantities by a manufacturer). Such decisions would be
distinct from largely regulatory determinations to allow sales of
a product through private-sector channels.
National decision-making processes for public policies, and
health policies more specifically, have been under study for
decades. They can be seen as complex, non-linear processes,
balancing evidence, policy alternatives and domestic and
international politics (Grindle and Thomas 1991; Walt 1994;
Kingdon 1995). Substantial efforts have been made to under-
stand and therefore improve decision-making processes (e.g.
DeRoeck 2004; DeRoeck 2005; Gericke et al. 2005; Bryson et al.
2010; Gessner et al. 2010; Grundy 2010; Levine et al. 2010a;
Victora 2010) and to generate the data needed by countries
to facilitate decision-making, including data on burden of
disease and on cost-effectiveness of interventions (e.g.
Hutubessy et al. 2003; WHO 2004; La Force et al. 2007;
Hajjeh et al. 2010; Kim et al. 2010; Levine et al. 2010b).
Countries also need to consider many factors specific to
the targeted disease and the characteristics of the intervention,
some of which are informed by international organizations
and global experts [e.g. World Health Organization (WHO)
policy positions; donor funding commitments] (WHO 2002;
WHO 2005; Stop TB Partnership and WHO 2007; Bryson et al.
2010; Shearer et al. 2010). Within countries, there may be
questions about co-ordination among different entities, par-
ticularly for an intervention that cuts across areas of special-
ization in public health. One example would be the human
papillomavirus (HPV) vaccine that has required collaboration
across reproductive health, immunization and school health
experts (Katahoire et al. 2008).
The track record for adoption decisions and implementation
of new health interventions in LMICs suggests that it takes
years or decades for many countries to realize the benefits of
new public health interventions (Kane and Brooks 2002;
Bosman and Mendis 2007; Frost and Reich 2009; Levine et al.
2010b; WHO et al. 2010). Decisions are likely more complex for
a novel, ‘first in class’ intervention like a malaria vaccine, but
less complex for a second-generation or follow-on intervention,
such as a new anti-malarial drug that is meant to replace a less
effective drug. While detailing the multiple reasons for these
delays is beyond the scope of this paper, a recurrent theme has
been the need for more thought during the development of a
health intervention on what processes and data LMICs would
need in order to make timely decisions on whether or not to
introduce the intervention.
Evidence that insufficient planning for country decision-
making is a major cause of delays in the use of health
interventions is apparent in a number of areas. The GAVI
Alliance (GAVI) has pinpointed challenges in decision-making
as a key factor in the delay to implement the Haemophilus
influenzae type b (Hib) conjugate vaccine (Mitchell et al. 2005;
Hajjeh et al. 2010), a vaccine available in the developed world
since 1987. The delay led GAVI in 2005 to invest US$37 million
in establishing the four-year Hib Initiative. The Initiative
provided support to countries wishing to decide if Hib vaccine
was a priority for introduction, and programmatic support to
countries which had already decided to use it (GAVI Alliance
2004). Reports on the process that is required to change malaria
treatment policy suggest that the policy decision process itself
takes 1 to 5 years, with an equal length of time for implemen-
tation (Williams et al. 2004; Mulligan et al. 2006; Amin et al.
2007; Bosman and Mendis 2007). One estimate suggests that
changing treatment is likely to cost roughly US$1 million in
today’s currency for a reasonably large country like Tanzania
(Mulligan 2006). Both GAVI and the Global Fund to Fight
AIDS, Tuberculosis and Malaria (GFATM), the world’s largest
organizations supporting adoption of new health interventions,
recognize the challenges country-level decision-makers face.
Proposals to either organization for support must demonstrate
the functioning presence of a local partner and government
co-ordination mechanism to support decision-making and
implementation (GAVI Alliance 2008; GFATM 2010). These
requirements would not be called for if those organizations did
not recognize the challenges inherent in national decision-
making processes.
Variability in the speed of adoption naturally exists between
situations and across countries. At the same time, accelerating
clinical trials to save 1 or 2 years on timelines to licensure of a
new intervention only to have the policy and implementation
process add years or decades suggests that more forethought is
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needed around national planning processes during intervention
development. Product developers, and countries and their
development partners, need to plan in advance for new
health interventions. This paper lays out a multi-year collabor-
ation designed to anticipate the processes and data that
countries would need to make decisions on whether or not to
introduce a malaria vaccine. Such work was called for by the
Malaria Vaccine Technology Roadmap, a plan laid out by 230
experts representing 100 organizations from 35 countries
(Malaria Vaccine Funders Group 2006). The roadmap recog-
nizes that anticipating national decision processes during the
vaccine development period is a critical part of making such a
novel intervention accessible to those most in need.
The most advanced malaria vaccine candidate (RTS,S) is
part-way through phase 3 clinical trials in Africa, the region
where an estimated 91% of the nearly 800 000 annual
malaria-related deaths occur, almost entirely among children
under 5 years of age (Vekemans et al. 2009; WHO 2010;
Agnandji et al. 2011). If all goes well, WHO has indicated that a
policy recommendation for RTS,S is possible as early as 2015,
and implementation through routine infant immunization
programmes in Africa could follow.
This paper describes the decision-making framework which
could be used for any upcoming malaria vaccine. The frame-
work was intended to understand what will be needed for
national governments of malaria-endemic countries to achieve
the following vision: to make timely and well-informed decisions
about the appropriate use of a malaria vaccine within their
national health systems within 1 to 3 years of licensure. It is likely
that the framework’s first application will be to RTS,S. This
paper reports on research to address the following specific
questions:
(1) What processes do national experts identify as needing to
take place for countries to decide on the use of a malaria
vaccine and when do they need to take place relative to the
projected availability of a vaccine?
(2) What data do national experts identify as needed for a
decision on the use of a malaria vaccine and when would
they need the data relative to projected availability of a
vaccine?
The paper will go on to discuss the lessons gained from
answering these questions for other new health interventions.
Methods
The decision-making framework guide was developed through
an iterative process from 2005 to 2008 (Figure 1). A series of 10
consultations, of 1 to 2 days, were convened in African
countries with up to 50 participants at each. The consultations
included plenary presentations allowing African scientists and
immunization, malaria, other government and partner staff,
and participants to discuss their shared experiences with taking
decisions on the adoption of malaria interventions, vaccines
and/or other public health interventions. Participants were also
provided with briefing papers on issues related to vaccine
development, the adoption of malaria control interventions and
new vaccines.
Facilitated break-out sessions, using broad categories drawn
from WHO’s Vaccine Introduction Guidelines (2005), allowed
participants to identify processes and data that would be
needed to take a decision to adopt, or not, a malaria vaccine,
and when these processes and data would be needed. No
similar, generic guidelines were identified by researchers for
malaria interventions. Break-out sessions at subsequent meet-
ings used the results of the first meeting as a starting point.
Plenary discussions were used to reach consensus on which
processes and data points were critical for policy development
and implementation decisions, and which were merely helpful.
Meeting reports were circulated back to all participants for
input prior to finalization and posting to a public website
(Malaria vaccine decision-making framework 2011).
Outcomes were analysed to identify consistent findings across
two or more country meetings. Outliers were considered
according to their merit relative to published and grey litera-
ture. Resulting processes and data points were put into a
regional decision-making framework guide that was validated
through consultations with 30 countries at 1-day, sub-regional
meetings of immunization and malaria experts. The process
was independently evaluated through an online survey using
qualitative and quantitative methods (Princeton Survey
Research Associates International 2008).
Results
Africa Regional Guide to a Malaria Vaccine
Decision-Making Framework
The validated regional guide identified 31 processes (26 critical
and 5 helpful) and 48 data points (39 critical and 9 helpful).
The processes and data were also categorized by accountability;
whether they should take place or be generated at international
(e.g. global or regional) or national level. Both processes and
data points are presented according to a timeline related to
product development, from as early as 5 years pre-licensure, to
the period around licensure and decisions on use, until 5 years
post-licensure if introduced. Figure 2 shows processes at
international and national levels. Figure 3 shows data, pre-
sented in seven categories based upon the WHO Vaccine
Introduction Guidelines (WHO 2005). It reflects data needed
for policy development: malaria disease burden; other malaria
interventions; malaria vaccine impact; economic and financial
issues; and malaria vaccine efficacy, quality and safety. Figure 3
also reflects data needed to inform implementation: program-
matic considerations and socio-cultural environment. The fre-
quency of process and data points identified by countries and
through the regional validation meetings are presented in
Tables 1 and 2.
National processes
An initial step identified during country consultations was to
establish national technical working groups with local experts
to work on the framework for malaria vaccines prior to
availability of the phase 3 data and licensure. When the
vaccine is licensed and a decision is being taken, such groups
will issue advice to inform the government’s policy decision.
The guide leaves it up to each country to determine the specific
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remit and membership of such groups where they are estab-
lished. Examples of the activities of such groups to date are
discussed below. Another critical, early process is the integra-
tion of planning for malaria vaccines into multi-year strategic
plans, such as for malaria and immunization. Other steps
during pre-licensure could include developing communications
plans, advocacy and engagement with local private-sector
partners. These activities become essential when the vaccine
is licensed and a decision on its introduction is being taken.
Monitoring vaccine performance, safety, implementation and
impact on the health system would take place during the period
after introduction. Additional national processes are identified
in Figure 2.
Global processes
The framework also identifies important processes to take place
at the global level, such as integrating country requirements
into product development plans to ensure the programmatic
suitability of a vaccine; global advocacy to fundraise for malaria
vaccines starting prior to licensure; and development of policy
recommendations and guidelines by WHO.
Figure 1 Timeline for decision-making framework (DMF) guide development process Note: MVI¼Malaria Vaccine Initiative; WHO¼World Health
Organization; RBM¼Roll Back Malaria.
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Data to inform policy development
Malaria disease burden
During country consultations, experts indicated that data
reflecting trends in malaria indicators at district-level would
be essential, as would age-stratification given that a vaccine
may not target all ages.
Other malaria interventions
Local data on the coverage, impact and cost-effectiveness of
other malaria interventions, as well as from international
organizations, were identified as critical before introduction of
a vaccine. It is critical to have updated estimates after
introduction to understand the relationship between the vac-
cine and ongoing investments in other preventive, diagnostic
and therapeutic interventions.
Malaria vaccine impact
Age-specific estimates of vaccine impact from international
organizations would be important in the policy decision process.
After introduction, local data on changes in mortality and
Table 1 Frequency of critical process responses from country consultations and regional validation meetings
Reported in country
consultations
(n¼ 10)
Reported in
regional validation
meetings (n¼ 3)
Pre-licensure period
National
Establish technical working group 4 2
Assess and strengthen regulatory, ethics and data management practices 5 3
Integrate the vaccine into countries’ multiyear strategic plans. Revise immunization and
national malaria control programme strategic plans
9 3
Global
Integrate country requirements into product development plans 10 3
Conduct global advocacy to leverage funding 2 2
Available data – Phase 3
Global
Share information on vaccine research 5 3
Conduct global advocacy to leverage funding 3 3
Licensure period
National
National regulatory authority reviews vaccine in consultation with technical working group 10 3
National expert group/technical working group issues recommendation on vaccine introduction 9 3
Conduct advocacy with national decision-makers and major stakeholders 8 3
Ministry of Health makes decision about integration of vaccine into immunization programme 8 3
Develop plan for procurement and resource mobilization for financial sustainability 5 3
Incorporate malaria vaccine into national budgeting processes 4 3
Update communication plan for implementation and engage media 9 3
Elaborate the vaccine introduction plan and programmatic guidelines 9 3
Examine sustainability of existing funding and how to encourage in-country financing 2 3
Engage media 2 1
Global
WHO issues policy recommending vaccine use 9 3
WHO publishes vaccine management and introduction guidelines 9 3
Donors provide funding to support vaccine 9 3
WHO issues prequalification 9 3
International agencies plan for procurement 9 3
Post-licensure period
National
Monitor vaccine performance and safety 10 3
Monitor vaccine implementation 9 3
Evaluation vaccine introduction impact on health system 8 3
Global
Monitor vaccine performance, including evaluation of impact, safety and pharmacovigiliance 6 3
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Table 2 Frequency of critical data responses from country consultations and regional validation meetings
Reported in
country
consultations
(n¼ 10)
Reported in
regional
validation
meetings
(n¼ 3)
Pre-licensure period
Malaria disease burden
Reported and confirmed cases by age group 10 3
Reported malaria-related deaths by age group 10 3
Malaria epidemiology profile by district 7 3
Malaria cases in pregnant women and HIVþ population 5 3
Other malaria interventions
Impact of current malaria interventions 10 3
Coverage of current malaria interventions 7 3
Cost-effectiveness estimates of current malaria interventions 9 3
Malaria vaccine impact
Impact on mortality and morbidity by age group 9 3
Economical and financial issues
Cost-effectiveness estimates of malaria vaccine 9 3
Malaria vaccine efficacy, quality and safety
Adverse events 9 3
Interaction with other vaccines 4 3
Efficacy 5 1
Programmatic considerations
Anticipated vaccine characteristics and presentation 9 3
Available data – Phase 3
Malaria vaccine impact
Marginal impact with other malaria interventions 9 2
Economical and financial issues
Vaccine price for public 8 3
Donor subsidy and sustainability of subsidy 9 3
National affordability 7 3
Malaria vaccine efficacy, quality and safety
Efficacy, impact: clinical and severe disease, anaemia and parasitaemia 8 3
Efficacy in HIVþ populations 4 3
Duration of efficacy 9 3
Programmatic considerations
Supply availability 8 3
Demand forecast 5 3
Heath system capacity to accommodate 4 3
Product characteristics and storage information 3 1
Licensure period
Malaria disease burden
Update on current malaria situation 2 1
Economical and financial issues
Sustainability of donor subsidy 7 3
Sustainable national commitment 10 3
Malaria vaccine efficacy, quality and safety
Efficacy, quality and safety data from other countries 1 2
Programmatic considerations
Defined target groups and communication plans 5 3
(continued)
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morbidity indicators as well as impact studies from other
countries will be essential to reinforce the decision.
Economic and financial issues
The most data points, nine critical and two helpful, were
identified for economic and financial issues. Cost-effectiveness
estimates of the malaria vaccine should be available as early as
the pre-licensure period. Early indication of the price and
impact on national health budgets; amount and sustainability
of donor subsidies; and indications of country affordability and
sustainability were identified as key elements that would be
taken into account in the policy development process. If
introduced, it is essential that international partners provide
updated estimates of cost-effectiveness, and that countries
generate data on socio-economic impact as well as recurrent
costs such as for surveillance.
Malaria vaccine efficacy, quality and safety
The guide for the decision-making framework on malaria
vaccines outlines a number of data that would be required from
vaccine developers for countries to develop a policy: efficacy
against clinical and severe disease; anaemia; and parasitaemia.
Impact on mortality was identified as an outcome of interest,
but not essential as a trial endpoint. If introduced, local data on
vaccine safety would be essential.
Issues to consider for implementation
Programmatic considerations
Information on anticipated vaccine characteristics and storage
requirements would be needed as early as the pre-licensure
period, as would be data on supply availability. National
demand forecasts and data on the national health system’s
ability to accommodate the vaccine (e.g. implications for the
cold chain) were identified as critical in the period prior to
licensure. Communications plans become increasingly import-
ant after a decision to adopt, as does ongoing evidence of a
secure vaccine supply.
Socio-cultural environment
Country experts identified the need for data on community
knowledge, attitudes and practice related to vaccines and
malaria before introduction, but it became critical during the
introduction period.
Summary findings of the external evaluation
Participants gave high marks for the development process for
the decision-making framework guide, with 90% indicating that
the guide will be extremely or very useful for the preparation
process prior to vaccine licensure, while 88% indicated it would
be extremely or very useful for making decisions after a vaccine
is licensed. In addition, 77% indicated it would be extremely or
very useful when considering the decision-making process for
other vaccines; 79% felt that the meeting facilitators were
neutral (neither promoting nor discouraging introduction of a
malaria vaccine).
Interestingly, 70% indicated that the timing of the prepar-
ation of the decision-making framework guide was about right,
5% indicated it was already too late and 25% felt it was too
early. The recommendations received from participants called
for similar meetings to support technical development and
Table 2 Continued
Reported in
country
consultations
(n¼ 10)
Reported in
regional
validation
meetings
(n¼ 3)
Post-licensure period
Malaria disease burden
Reported and confirmed clinical and severe malaria cases by age group 7 3
Other malaria interventions
Changes in impact and cost-effectiveness of other anti-malaria interventions 2 1
Malaria vaccine impact
Vaccine coverage: use of morbidity and mortality indicators for impact studies 10 3
Effectiveness, including impact on clinical and severe disease, anaemia and parasitaemia 8 3
Economical and financial issues
Socio-economic impact 10 3
Updated malaria vaccine cost-effectiveness data 9 3
Estimates of recurrent costs, including marketing and surveillance 5 3
Malaria vaccine efficacy, quality and safety
Post-licensure safety and efficacy data 10 3
Programmatic considerations
Evidence of supply security 4 3
Socio-cultural environment
Community knowledge, attitudes and practices related to vaccines and malaria interventions 6 3
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central co-ordination of the information identified in the
decision-making framework guide.
Discussion
The research described above demonstrates that it is possible to
plan for national decision-making for a new intervention and
that African health officials value this process. The research also
shows that developers, partners and countries should begin to
consider requirements for decisions at least 3 to 5 years before
an intervention is anticipated to be approved by the appropriate
regulatory authorities. The actual timing of a decision relative
to licensure, as well as the ultimate process, will vary among
countries and interventions. Use of a guide developed jointly
with countries to establish the decision framework should
increase the likelihood of timely, evidence-based decisions, but
will not guarantee such an outcome.
After the Africa regional guide was validated by countries
in 2008, MVI engaged a number of malaria and immunization
programme managers within African health ministries,
and other national stakeholders, in a discussion on how to
start working on the requirements that will guide a decision on
a possible first-generation malaria vaccine. Burkina Faso,
Ghana, Tanzania and Uganda organized technical working
groups to co-ordinate the process. The focus of the working
groups is to assemble the evidence needed for a policy
formulation and ensure systems are in place for a smooth
decision-making process. Under the guidance of each group’s
chair, they develop annual or bi-annual work plans, and
members may choose to carry out the planned activities
within their own institutions or they may seek services
elsewhere. Composition and their modes of operating vary,
but common features include: (1) They are linked to an existing
group within the malaria control or immunization programmes;
(2) Members are from Ministries of Health, research institutes
and universities, and partner organizations (e.g. WHO country
offices); (3) They are officially established by the senior
management at the Ministry of Health: and (4) They report
to an existing advisory body to the Ministry of Health. In
Ghana and Burkina Faso, the co-ordination is led by the
National Malaria Control Program and WHO. In the two other
countries, the co-ordination is led by local, parastatal research
institutions.
The process for the malaria vaccine decision-making frame-
work benefited from a commitment to create a guide, building
upon existing WHO guidelines, that was generic to any malaria
vaccine to come, and a focus on all vaccines under development
instead of only one potential product (WHO 2005). Only after
the guide was validated was there discussion of its application
to specific products. The guide adapted the WHO guidelines for
introducing new vaccines. This suggests that the requirements
for malaria vaccines are not completely unique, but that the
general requirements need specificity to the context of malaria
vaccines. Some aspects need emphasis while others will not.
For example, there was relatively little data from developing
countries on the epidemiology and burdens of disease that
could be prevented by Hib, rotavirus and pneumococcal
conjugate vaccines, while malaria is relatively well studied.
Therefore, the question was not if malaria was a problem but
how would a vaccine perform in different epidemiological
settings and what would be its additional benefit in the context
of other interventions. This contrasts to Hib and pneumococcal
diseases where there are no widely available, preventive
measures other than vaccines.
The iterative nature of such a process creates an important
forum for those who may not normally collaborate, for reasons
that may include different specialties in public health and splits
between researchers and implementers, academia and govern-
ment (DeRoeck 2004; Amin et al. 2007). By creating a forum
with a shared technical task, each group is able to apply its
unique skills to the shared technical challenge, which also
strengthens and prepares messages informing policy. A shared
process was particularly important for bridging the
long-established disciplines of malaria and immunization,
similar to the challenge identified previously for HPV vaccines.
Such a challenge may not be faced by other vaccines or those
working only in the malaria community.
One valuable outcome of research to plan early for decision-
making is the voice that countries can have. The process
provides a structured means for countries to provide their input
to those developing interventions. By identifying critical
processes and data and by assigning responsibility to the
international level, countries are signaling their expectations of
developers and international organizations. The process identi-
fies areas, such as the product profile, in which countries would
like to explicitly inform the work of developers, and it helps
countries understand when such contributions are possible (i.e.
years before an intervention is available.) Identifying the
elements for which countries feel they should be held
accountable informs and strengthens national planning cap-
acity and management processes, and provides a means for
local researchers to collaborate and seek complementarities in
their research.
Researchers will need to consider sought-after data in light of
its feasibility. Some types of data, for example re-stratifying
age-specific malaria mortality data which is typically aggregated
and reported for all children under 5, may not be difficult.
Others may come from modelling or extrapolation from other
countries. Prioritizing the data as critical vs helpful was
intended to help prioritize data collection efforts.
The process of developing a guide to describe the malaria
vaccine decision-making framework also illustrated some of the
challenges inherent in planning for decisions on an intervention
that is still under development. The most significant challenges
relate to the time constraints of national staff in light of current
programme priorities, to risks of interventions failing in late
development and to over-promising by developers, each of
which are elaborated below.
LMIC health system managers are typically pulled in multiple
directions, responding to the immense challenges faced every
day. It is essential to find an appropriate balance, not asking for
too much time focused on interventions not yet available, while
seeking concrete input to ensure that future interventions will
meet programme needs. Because of the many time constraints,
concrete planning activities will generally require a local
organization or part of the government to fill a secretariat
and co-ordination role. This was described in the previous
section.
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Planning in advance also means helping programme staff and
collaborators at country level understand that a new interven-
tion, particularly a novel one, could fail at any time. Time spent
on a new intervention is invested ‘at-risk’. For example, a safety
concern might arise during late clinical trials or efficacy may
not be seen in certain populations, stopping development of the
intervention such that time invested might be considered
partially wasted.
Development timelines, and to a lesser extent final inter-
vention characteristics, are notoriously difficult to predict.
Countries need to understand that timelines are rarely
shortened, and that they are more typically lengthened by
years.
The challenges considered in the previous paragraphs can
be mitigated by transparency, education and care in not
letting decision planning activities get ahead of accumulated
scientific evidence. Taken together, these three challenges
necessitate a cautious, carefully planned approach when
discussing future health interventions with national
decision-makers.
Another challenge is to properly contextualize discussions on
a new health intervention relative to existing health interven-
tions targeting the same disease, to other interventions of the
same modality (e.g. drugs, vaccines) and to priorities within the
wider health system (WHO 2005; Stop TB Partnership and
WHO 2007). A novel intervention like a malaria vaccine will
enter a complex arena of existing malaria control measures,
and an environment of multiple new vaccines being considered
by countries. In some cases, interventions may replace existing
ones (e.g. an improved medication), although perhaps it is
more cautious to assume a new intervention will co-exist for at
least some time with others. For this reason, those supporting
early planning should be well-versed in other interventions, not
be seen to be pushing a single product onto countries to the
exclusion of other approaches.
The basic processes and lessons described above are relevant
for novel health interventions under development. Second-
generation or follow-on interventions may not require the same
level of research over multiple years. Precedents and advisory
bodies may already exist (Gessner et al. 2010). Data may already
have been collected on many essential aspects. However, a
structured approach to confirm the processes and data needed,
and the relevant timelines, remains a valuable step during the
development period of an intervention.
Such exercises do not guarantee that policy decisions will be
based only on evidence and all countries will go through a
predictable process. Political decisions in some situations will
triumph other factors (Kingdom 1995). It is recognized that
decisions are influenced by many political, societal and insti-
tutional factors. Experts consulted in the development of the
guide highlighted that global level advocacy must begin early
and that local implementation of strategies for advocacy,
communications, and outreach to private-sector and pharma-
ceutical companies should start well before a decision would be
taken.
A structured approach provides clear insights into what data
countries will need for a decision (DeRoeck 2004). It informs
the work of those developing an intervention, allowing the
clinical activities to respond to questions for public policy as
well as regulatory requirements. It is a capacity building and
health systems strengthening exercise creating a pool of
expertise to inform government decisions after the intervention
is available, while allowing greater clarity on roles and
responsibilities for different stakeholders and parts of
government.
The outcome of the decision planning process may lead to the
decision to adopt, or not, the intervention. Countries with
timely ‘no’ decisions help international funding bodies, pro-
curement agencies and manufacturers as they do their own
long-term planning. Countries that are undecided can be the
most challenging for these bodies.
Conclusion
This paper argues for the importance of early planning for
country decisions on new health interventions. Malaria vaccines
provide one example of an approach and multiple lessons,
identified above, should be considered for other new interven-
tions. While there is always a risk that an intervention under
development fails, a small amount of time invested in planning
for its possible use has the promise to pay off immensely down
the road. This paper seeks to determine which planning steps
are appropriate and reasonable to take prior to intervention
availability. It argues that such an approach holds promise for
better public health decisions and greater public health impact
through accelerated and informed decisions on the use of a new
intervention once available.
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